Grace Therapeutics (GRCE) Price to Sales (2020 - 2021)
Grace Therapeutics' (GRCE) quarterly Price to Sales came in at 618.93 in Q1 2021, up 37.52% quarter-over-quarter from 450.06 in Q4 2020.
Powered by 
Analysis
Grace Therapeutics (GRCE) Price to Sales (2020 - 2021) Analysis & Trends
Grace Therapeutics has disclosed Price to Sales across 2 years of filings, most recently posting 618.93 for Q1 2021.
- In Q1 2021, Price to Sales changed N/A year-over-year to 618.93; the TTM figure through Mar 2022 stood at 229.33 (changed N/A YoY), while the FY2021 annual figure was 363.15, changed N/A from the prior year.
- Price to Sales came in at 618.93 for Q1 2021 at Grace Therapeutics, up from 450.06 in the prior quarter.
- In the past five years, Price to Sales ranged from a high of 618.93 in Q1 2021 to a low of 450.06 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Grace Therapeutics | 39.38 Mn | 39.38 Mn | - |